Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Janina TAENZLER"'
Publikováno v:
Parasites & Vectors, Vol 11, Iss 1, Pp 1-4 (2018)
Abstract Background The efficacy of the fixed combination of fluralaner plus moxidectin for the treatment of Otodectes cynotis infestations was evaluated in cats after topical application. Methods Sixteen cats experimentally infested with O. cynotis
Externí odkaz:
https://doaj.org/article/08ff3fdc6ae44489934dc34cd2a6301c
Autor:
Heike Kohler-Aanesen, Seppo Saari, Rob Armstrong, Karine Péré, Janina Taenzler, Eva Zschiesche, Anja R Heckeroth
Publikováno v:
Parasites & Vectors, Vol 10, Iss 1, Pp 1-7 (2017)
Abstract Background The clinical efficacy of fluralaner chewable tablets (Bravecto™, MSD Animal Health) against naturally acquired Linognathus setosus infestations on dogs was evaluated compared with permethrin (Exspot®, MSD Animal Health) treatme
Externí odkaz:
https://doaj.org/article/97eaac4f0095446286d46618249ce7e5
Publikováno v:
Parasites & Vectors, Vol 8, Iss 1, Pp 1-6 (2015)
Abstract Background The preventive effect of fluralaner chewable tablets (Bravecto™) against transmission of Babesia canis by Dermacentor reticulatus ticks was evaluated. Methods Sixteen dogs, tested negative for B. canis by PCR and IFAT, were allo
Externí odkaz:
https://doaj.org/article/8ac924acfb6b46f788045acdd7479c35
Autor:
Heike Williams, Janina Demeler, Janina Taenzler, Rainer K.A. Roepke, Eva Zschiesche, Anja R. Heckeroth
Publikováno v:
Parasites & Vectors, Vol 8, Iss 1, Pp 1-8 (2015)
Abstract Background Fluralaner is a new antiparasitic drug that was recently introduced as BravectoTM chewable tablets for the treatment of tick and flea infestations in dogs. Most marketed tick products exert their effect via topical application and
Externí odkaz:
https://doaj.org/article/e7ec0f61f09f4a768f82f446decc13bc
Autor:
Josephus J Fourie, Julian E Liebenberg, Ivan G Horak, Janina Taenzler, Anja R Heckeroth, Regis Frénais
Publikováno v:
Parasites & Vectors, Vol 8, Iss 1, Pp 1-7 (2015)
Abstract Background This laboratory study compared the efficacy of Bravecto™ (fluralaner), formulated as a chewable tablet, with the efficacy of Advocate® (imidacloprid/moxidectin), formulated for topical administration, against naturally acquired
Externí odkaz:
https://doaj.org/article/2a938704351b4971bb2c7be86d7f4b72
Autor:
Janina Taenzler, Christina Wengenmayer, Heike Williams, Josephus Fourie, Eva Zschiesche, Rainer KA Roepke, Anja R Heckeroth
Publikováno v:
Parasites & Vectors, Vol 7, Iss 1, Pp 1-4 (2014)
Abstract Background Fluralaner (Bravecto™) is a novel systemic insecticide and acaricide that provides long persistent antiparasitic activity following a single administration at the minimum dose of 25 mg/kg body weight. Methods Three negative cont
Externí odkaz:
https://doaj.org/article/1dadc75030b644dfbc53bc1f93ab63d9
Publikováno v:
Parasites & Vectors
Parasites & Vectors, Vol 11, Iss 1, Pp 1-4 (2018)
Parasites & Vectors, Vol 11, Iss 1, Pp 1-4 (2018)
Background The efficacy of the fixed combination of fluralaner plus moxidectin for the treatment of Otodectes cynotis infestations was evaluated in cats after topical application. Methods Sixteen cats experimentally infested with O. cynotis were allo
Publikováno v:
Parasites & Vectors
Background The efficacy of fluralaner for the treatment of Otodectes cynotis infestations in dogs and cats was evaluated after oral (dogs) or topical administration (dogs and cats). Twenty-four dogs and sixteen cats were experimentally infested with
Autor:
Anja Regina Heckeroth, Rainer K. A. Roepke, Janina Taenzler, Régis Frénais, Julian Liebenberg
Publikováno v:
Parasites & Vectors
Background The efficacy of fluralaner, formulated as a chewable tablet (Bravecto™) or topical solution (Bravecto™ Spot-on Solution), was evaluated against naturally acquired Sarcoptes scabiei var. canis infestation in dogs. Methods The study was
Publikováno v:
Parasites & Vectors
Background Fluralaner spot-on solution provides immediate and persistent efficacy against tick and flea infestations in dogs and cats for 12-weeks following topical administration. The active ingredient fluralaner is distributed systemically followin